Min 11:45 @ Oct. 20th, 2020 CC.
Can be found in the IR Calendar link on the website:
" As Nader said, there was the DSMC meeting last Thursday
and during the the intro to the meeting, I had asked the members of the committee
to look @ the clinical signals, mortality signals and to specifically address weather we
needed to adjust the dosing. When we had submitted CD10 & CD12, we had proposed
2 doses for the mild to moderate patients, 4 doses for the severe & critical & the FDA
pushed back having to give 2 doses for both study populations. I've never actually been
comfortable with that, and so the question i asked the committee was, was there a signal
that might require Cytodyn to adjust the CD12 dosage. Are there patients who, particularly
critical patients, who might need a 3rd or 4th dose of Leronlimab ?